Artificial intelligence-driven drug discovery company Isomorphic Labs has secured $2.1 billion in fresh funding as it ramps up efforts to transform pharmaceutical research using advanced AI technologies. The London-based startup, which was spun out of Google DeepMind in 2021, is positioning itself as one of the leading companies applying artificial intelligence to accelerate the development of new medicines and treatments.
The funding round was led by Thrive Capital, with participation from existing investors Alphabet and Google Ventures, along with new backers including MGX, Temasek, CapitalG, and the UK Sovereign AI Fund. The massive investment highlights growing global confidence in AI-powered healthcare innovation and the potential of artificial intelligence to significantly reduce the time and cost involved in traditional drug discovery processes.
Founded by DeepMind CEO Demis Hassabis, Isomorphic Labs builds upon the success of AlphaFold, the groundbreaking AI system capable of predicting protein structures with remarkable accuracy. The company has since expanded these capabilities through its proprietary AI drug design engine known as IsoDDE, which integrates protein structure prediction, molecular interaction modeling, and binding affinity analysis into a unified platform for pharmaceutical research.
According to reports, the newly raised capital will be used to scale the company’s AI drug design engine, expand therapeutic development programs, and support hiring across engineering, AI research, and clinical operations. Isomorphic Labs currently operates from locations in London, Cambridge, Massachusetts, and Lausanne, Switzerland, and has already formed partnerships with major pharmaceutical companies including Eli Lilly and Novartis to advance AI-assisted drug development.
Industry experts believe AI-powered drug discovery is becoming one of the most promising applications of artificial intelligence in healthcare. Pharmaceutical companies worldwide are increasingly investing in AI systems capable of shortening research timelines, identifying promising drug candidates faster, and improving the efficiency of clinical development. Analysts suggest the growing adoption of AI in biotech and life sciences could reshape how future medicines are discovered and brought to market.
The company also revealed that it now expects its first AI-designed drugs to enter clinical trials by the end of 2026. While this timeline is slightly later than earlier projections, the announcement demonstrates the rapid progress being made in integrating AI into real-world pharmaceutical development. As global investment in AI healthcare technologies continues rising, Isomorphic Labs is emerging as one of the most closely watched companies at the intersection of artificial intelligence and biotechnology.
